NURAVAX

Our team at Nuravax is not just at the forefront of developing innovative solutions for neurological diseases; we are also leading contributors to the scientific community. Our experts have a rich history of publishing an extensive array of studies, demonstrating our deep commitment to advancing knowledge in our field... At Nuravax, our research pipeline is robust and forward-thinking, dedicated to developing vaccines for individuals at risk of Alzheimer's disease, tauopathies, Parkinson's disease, and other α-synucleopathies. Our projects are fueled by prestigious grants, including NIA and NINDS R21s, R01s, and U01 awards, reflecting the trust and recognition in our scientific community... At NURAVAX, we believe in the power of immunotherapy as a groundbreaking approach to treat Alzheimer's and Parkinson's diseases. Our focus is on developing vaccines to stimulate the body's own immune response against key pathological factors: beta-amyloid, tau proteins, and a-synuclein.

Primary location: Irvine United States